Jane Street Group, LLC Cyma Bay Therapeutics, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $1.72 Million - $3.34 Million	136,320 Added 232.44%	194,968 $4.61 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $347,628 - $564,016	32,010 Added 120.17%	58,648 $874,000
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $4.07 Million - $5.97 Million	-544,861 Reduced 95.34%	26,638 $291,000
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $2.69 Million - $4.39 Million	457,816 Added 402.71%	571,499 $4.98 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $329,824 - $642,236	102,430 Added 910.25%	113,683 $712,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $2,767 - $4,245	-999 Reduced 8.15%	11,253 $39,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $2,767 - $4,245	-999 Reduced 8.15%	11,253 $39,000
Q2 2022 Aug 16, 2022	BUY	$1.72 - $3.39 $21,073 - $41,534	12,252 New	12,252 $36,000
Q3 2021 Nov 16, 2021	SELL	$3.47 - $4.42 $52,344 - $66,675	-15,085 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.94 - $4.92 $82,137 - $102,567	-20,847 Reduced 58.02%	15,085 $66,000
Q1 2021 May 18, 2021	SELL	$4.23 - $6.55 $323,303 - $500,623	-76,431 Reduced 68.02%	35,932 $163,000
Q4 2020 Feb 17, 2021	BUY	$5.73 - $9.03 $367,401 - $578,994	64,119 Added 132.91%	112,363 $645,000
Q3 2020 Nov 17, 2020	BUY	$3.32 - $7.24 $160,170 - $349,286	48,244 New	48,244 $349,000
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $98,628 - $159,384	-78,903 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $104,940 - $467,894	78,903 New	78,903 $155,000
Q2 2019 Aug 15, 2019	SELL	$6.05 - $13.66 $197,369 - $445,630	-32,623 Closed	0 $0
Q1 2019 May 16, 2019	BUY	$8.16 - $13.42 $266,203 - $437,800	32,623 New	32,623 $433,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account